Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

              Author:Hershey, Andrew D.   Szperka, Christina L.   Barbanti, Piero   Pozo-Rosich, Patricia   Bittigau, Petra   Barash, Steve   Garnett, Sally   Bryson, Juline   Kessler, Yoel   Carmeli Schwartz, Yael   Ning, Xiaoping   

              Session Name:PL5: Clinical Trials Plenary Session  

              Topic:Headache  

              Program Number:PL5.001  

              Author Institution:Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH  Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Headache and Pain Unit, IRCCS San Raffaele, Rome, Italy, and San Raffaele University, Rome, Italy, Rome, Italy  Headache Unit and Research Group, Vall d’Hebron Hospital and Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain, Barcelona, Spain  Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA, West Chester, PA  Teva Pharmaceutical Industries Ltd., Tel Aviv, Israel, Tel Aviv, Israel  

              Interim Analysis of CONFIDENCE: A ProspeCtive ObservatioNal Study with Acute Treatment oF rImegepant ODT on ConsistENcy, SatisfaCtion and Tolerability of TrEatment in the Real World

              Author:Abraham, Lucy   Urani, Alexandre   Lambru, Giorgio   Lipton, Richard   Goadsby, Peter   Pozo-Rosich, Patricia   Schwedt, Todd   Galabova, Boryana   Dai, Feng   Hygge Blakeman, Karin   

              Session Name:P10: Headache: Advances in CGRP Inhibitors and Migraine 3  

              Topic:Headache  

              Program Number:P10.001  

              Author Institution:Pfizer R&D UK Ltd, Tadworth, Surrey , Tadworth, United Kingdom  Aptar Digital Health, Paris, France, Rueil Malmaison, France  The Headache and Facial Pain Service, Guy's and St. Thomas' NHS Foundation Trust, London, UK, London, United Kingdom  Montefiore Medical Center and Albert Einstein College of Medicine, New York, USA, Bronx, NY  NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital/SLaM Biomedical Research Centre, King’s College London, UK and UCLA, Los Angeles, CA, USA, Los Angeles, CA  Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona  Headache and Craniofacial Pain Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA, Phoenix, AZ  Pfizer R&D UK Ltd, Tadworth, Surrey, London, United Kingdom  Pfizer AB., Stockholm, Sweden, Stockholm, Sweden